바이오스펙테이터

by Jongwon Jang

SEERS Technology succeeded in attracting 3 billion won in investment. Subsequently, the Cardiac Monitoring Solution 'mobicCARE + Cardio' has also acquired the European CE certification, opening the way to enter not only the domestic market but also the global market.

SEERS Technology is Korean digital healthcare company that has pioneered the global market with remote patient monitoring-based telehealth solutions.

According to SEERS Technology Corp. on March 2nd, the company recently attracted a 3 billion won investment from Life Core Partners, an asset management company specializing in bio-healthcare. The company has completed a total of 7 billion won in Series A investment, including 4 billion won received from Winvest last year. Investors particularly valued the potential of SEERS' accumulated technology and telehealth solutions "mobicCARE + Home" and "mobicCARE + Cardio" for growth.

Established in 2009 as a living witness to domestic telehealth market, SEERS has developed and supplied remote patient monitoring solutions for the past decade to the domestic and international healthcare markets. They have experienced several difficulties in revising the medical law for the introduction of telehealth to Korea, but have seen breakthroughs in the global market.

SEERS' core business area is “mobicCARE + Home”, a remote patient management solution. MobicCARE + Home is a solution that includes applications for patients (self-measurement, online triage and education) and physician (e.g., patient information, online prescription, etc.) and 'telehealth gateway' equipment that are linked to a variety of personal health devices such as blood pressure meter, blood glucose meter, scale, oxygen saturation meter, and lung capacity meter. MobicCARE + Home helps patients with chronic diseases easily receive medical treatment and receive medication at home, as well as manage their health.

After receiving the certification as Korea’s first telehealth solution in 2010 for the mobicCARE + Home in 2010 by KFDA, SEERS has entered the global market through certification in Europe (2012) and US (2013). In the meantime, SEERS has participated in telehealth pilot services in the United States, France, Germany, Thailand, Australia, and elsewhere, and has been supplying mobicCARE + Home to the Home Telehealth Service of the United States National Service since 2017. Since 2019, Oman and Vietnam have been determined as business base countries, and discussions are underway to advance into the local market.

The solution SEERS fosters as their next-generation business is "mobicCARE + Cardio". MobicCARE + Cardio is a heart disease monitoring solution using a wearable biosensor. Analyzed via artificial intelligence algorithm-based cloud, a web service solution that collects ECG, heart rate, heart rate change, respiration, body temperature, and other vital signals through the chest-attached biopatch assists medical staffs read out the conditions and solution for patients is provided in the form of mobile application. Their biopatch was approved as a second-class medical device by MFDS last year, and recently received European CE certification. The company explained that CE certification for ECG patches was the first among Korean companies.

Using mobicCARE + Cardio, an ECG test is possible for diagnosis of arrhythmia. In the case of the existing Holter Monitor test, the equipment was expensive, and the noise for motion artifact and other factors made it difficult for medical staffs and patients to use it conveniently.

Marticia Jo, director of SEERS said that “MobicCARE + Cardio is differentiated not only in biopatches, but also in solutions that support medical staffs and patients through analysis based on artificial intelligence algorithms. And ours is easy to wear and reusable which enables to supply at low cost. " SEERS is currently conducting related research in three Korean medical institutions and in Vietnam and Oman and plans to expand their scope to include bed monitoring solutions and post-discharge patient care solutions.

According to Luke Lee, CEO of SEERS Technology, overseas sales will begin in earnest following the European CE certification. The European and Middle East regions will be the first to be supplied. Not only replacing the existing Holter Monitor market, but it will also cover the unsatisfied markets such as atrial fibrillation diagnosis and medical checkups for stroke patients who had difficulty in testing due to inconvenience in existing solutions.